Last reviewed · How we verify
NCT06581159
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Phase 1 trial testing HS135 in Heart Failure With Preserved Ejection Fraction in 4 participants. Terminated before completion.
29 July 2025
Quick facts
| Lead sponsor | 35Pharma Inc |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 4 |
| Start date | 23 January 2025 |
| Primary completion | 29 July 2025 |
| Estimated completion | 29 July 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- HS135 — full drug profile →
- Placebo
Conditions studied
- Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Sponsor
35Pharma Inc — full company profile →
Who can join
18 and older, any sex, with Heart Failure With Preserved Ejection Fraction or Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06581159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HS135
Trials testing the same drug.
- NCT06493461 — A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults · Phase 1 · terminated
Other recruiting trials for Heart Failure With Preserved Ejection Fraction
Currently open trials in the same condition.
- NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
- NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
- NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
- NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
- NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting
Other 35Pharma Inc trials
Trials by the same sponsor.
- NCT06714825 — Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects · Phase 1 · completed
- NCT06493461 — A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06581159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by 35Pharma Inc
- Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06581159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing